Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,641,625
+$2,731,224 QoQ
Shares Held
2,104,986
+1474.6% QoQ
Ownership
3.14%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#7
of 60 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. ENGN ranks #90 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,804,703 | $240,494,721 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
960,863 | $117,782,586 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,157,008 | $111,726,513 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,330,716 | $89,802,487 | |
| 5 | ZLAB |
Zai Lab Ltd
|
3,369,034 | $64,011,646 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,288,053 | $47,799,646 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,222,080 | $45,730,233 | |
| 8 | CYTK |
Cytokinetics Inc
|
457,907 | $39,009,097 |
All Filings in ENGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,641,625 | 2,104,986 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $910,401 | 133,686 | Shares | Sole | 2026-05-18 | |
| 2025-06-30 | $101,144 | 27,787 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $106,619 | 23,799 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $13,002 | 1,970 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $5,658 | 600 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||